1. A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers
- Author
-
Charlotte Zoe Angel, Shannon Beattie, Ezanee Azlina Mohamad Hanif, Micheal P. Ryan, Francisco D. C. Guerra Liberal, Shu-Dong Zhang, Scott Monteith, Niamh E. Buckley, Emma Parker, Shannon Haynes, Alexander J. McIntyre, Paula Haddock, Madina Sharifova, Cristina M. Branco, and Paul B. Mullan
- Subjects
Medicine ,Cytology ,QH573-671 - Abstract
Summary In our study, we focused on a particular subtype of aggressive breast cancer called Triple-Negative Breast Cancer (TNBC). We investigated a complex series of events that contribute to poor outcomes in this disease and uncovered a crucial signaling cascade driving tumor growth and progression. At the core of this signaling cascade are three key proteins: SRC, AKT, and ERK2. Together, they form a pathway that activates a transcription factor called Slug. Transcription factors act like molecular switches, controlling the expression of genes. Once Slug is activated, it strongly suppresses genes that would normally restrict cell growth and cell spread. One of the genes downregulated by Slug is TGFB2-AS1. This product of the TGFB2-AS1 gene normally controls levels of its target protein called TGF-beta2 (TGFB2), a protein which has roles in cell growth, cell migration and differentiation. Slug downregulation of TGFB2-AS1 results in higher TGFB2 levels, and this in turn contributes to the uncontrolled growth and spread of cancer cells. TGFB2, and other proteins in this pathway (SRC, AKT, ERK2, and a Slug interactor called LSD1) all maintain the stability of Slug, meaning that Slug levels remain high and drive the aggressive features of this subtype of breast cancer. Overall, our research sheds light on the intricate molecular mechanisms driving aggressive TNBC. It also identifies potential targets for future therapies, aimed at disrupting this harmful signaling pathway and potentially improving patient outcomes for this disease.
- Published
- 2024
- Full Text
- View/download PDF